Schwartz Investment Counsel Inc. Increases Position in Zoetis Inc. $ZTS

Schwartz Investment Counsel Inc. lifted its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 6.8% during the fourth quarter, Holdings Channel reports. The fund owned 267,000 shares of the company’s stock after purchasing an additional 17,000 shares during the quarter. Schwartz Investment Counsel Inc.’s holdings in Zoetis were worth $33,594,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Global Wealth Strategies & Associates purchased a new stake in shares of Zoetis during the fourth quarter worth about $25,000. Lodestone Wealth Management LLC purchased a new stake in shares of Zoetis during the fourth quarter worth about $30,000. KERR FINANCIAL PLANNING Corp purchased a new stake in shares of Zoetis during the third quarter worth about $31,000. Holos Integrated Wealth LLC purchased a new stake in shares of Zoetis during the fourth quarter worth about $32,000. Finally, Board of the Pension Protection Fund purchased a new stake in shares of Zoetis during the fourth quarter worth about $38,000. 92.80% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Zoetis

In other Zoetis news, Director Michael B. Mccallister acquired 3,000 shares of the firm’s stock in a transaction that occurred on Monday, May 11th. The stock was acquired at an average cost of $77.76 per share, with a total value of $233,280.00. Following the acquisition, the director directly owned 24,524 shares of the company’s stock, valued at $1,906,986.24. This represents a 13.94% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.22% of the stock is owned by company insiders.

Analyst Ratings Changes

ZTS has been the subject of several research analyst reports. Piper Sandler reissued a “neutral” rating and issued a $135.00 price objective (down from $190.00) on shares of Zoetis in a report on Thursday, January 22nd. William Blair reissued an “outperform” rating on shares of Zoetis in a report on Monday, March 2nd. Bank of America boosted their price objective on Zoetis from $135.00 to $140.00 and gave the company a “neutral” rating in a report on Friday, February 13th. Citigroup initiated coverage on Zoetis in a report on Wednesday, April 15th. They issued a “buy” rating and a $145.00 price objective for the company. Finally, Wall Street Zen lowered Zoetis from a “buy” rating to a “hold” rating in a report on Saturday, May 2nd. Seven investment analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Zoetis currently has an average rating of “Hold” and a consensus price target of $141.25.

Zoetis Stock Up 0.3%

NYSE:ZTS opened at $76.92 on Wednesday. Zoetis Inc. has a 52 week low of $75.11 and a 52 week high of $172.23. The firm has a market capitalization of $32.25 billion, a PE ratio of 12.76, a price-to-earnings-growth ratio of 1.25 and a beta of 0.87. The stock has a 50 day moving average of $115.42 and a 200-day moving average of $122.28. The company has a current ratio of 3.15, a quick ratio of 1.91 and a debt-to-equity ratio of 2.80.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Thursday, May 7th. The company reported $1.53 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.60 by ($0.07). Zoetis had a return on equity of 66.85% and a net margin of 27.80%.The business had revenue of $2.26 billion during the quarter, compared to the consensus estimate of $2.30 billion. During the same period last year, the company earned $1.48 earnings per share. The business’s quarterly revenue was up 2.9% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. Analysts predict that Zoetis Inc. will post 6.9 EPS for the current year.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.